W.GroenewaldJ
Tirzepatide (commonly known as Mounjaro or Zepbound) a newer option that targets both GLP-1 and GIP receptors, often leading to even greater weight loss compared to semaglutide
Some patients may experience nausea or mild gastrointestinal discomfort, which typically resolves over time
(It is unclear when that will happen, but there is evidence it may not be far off: Novo Nordisk, which makes Wegovy and Ozempic using semaglutide, has recently increased supply of most dosages of the meds in the US.) The cost of drugs does not factor into whether they are in official shortage or not, but the affordability of these medications is directly connected to how accessible many patients find them
In a clinical trial, people on tirzepatide experienced an average of 15% weight loss on 5 mg, 19% on 10 mg, and 21% on 15 mg
Mens Health & Recovery with Dr